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Introduction {#sec005}
============

The Global Health Sector Strategy (GHSS) for viral hepatitis 2016--2021 calls for the elimination of viral hepatitis as a public health threat, reducing new infections by 90% and mortality by 65% by 2030 \[[@pone.0233446.ref001]\]. The WHO Western Pacific region including Vietnam bears the highest burden of Hepatitis C virus (HCV) globally, with approximately 19.2 million chronic infections \[[@pone.0233446.ref001]\]. The introduction of direct-acting antiviral agents (DAAs) has revolutionized HCV treatment and increasing numbers of patients are being treated. Several phase III clinical trials (Neutrino, Fission, and Valence) have demonstrated the efficacy, simplicity, and tolerability of DAAs \[[@pone.0233446.ref002]--[@pone.0233446.ref004]\] in the treatment of HCV in well-resourced setting. The sustained virologic response rate (SVR), defined as an undetectable viral load 12 weeks after completion of treatment and considered to represent cure, is consistently above 90% for most HCV-infected patient populations \[[@pone.0233446.ref005], [@pone.0233446.ref006]\].

HCV is classified into 7 genotypes, and these have specific geographical distributions. HCV genotype 6 is largely confined to China and southeast Asia, including Vietnam, Laos, Cambodia, Myanmar, Taiwan and the southern Chinese provinces of Guangxi, Guangdong and Hainan \[[@pone.0233446.ref007],[@pone.0233446.ref008]\]. Thirty-one subtypes of genotype 6 have been recognized in the region, indicating a local emergence and evolution \[[@pone.0233446.ref009]\]. In the south of Vietnam, up to 60% of HCV infections are caused by genotype 6 \[[@pone.0233446.ref010]\] and therefore the success of HCV elimination in the region depends upon the effectiveness of DAA combinations against this genotype. While a number of DAAs, such as Sofosbuvir (SOF), are believed to have antiviral effects that are independent of the virus genotype, there are limited data on the efficacy of DAA treatments for HCV genotype 6 infections. This reflects the limited numbers of patients with the genotype recruited into clinical trials \[[@pone.0233446.ref011], [@pone.0233446.ref012]\]. While studies from New Zealand and Hong Kong that have included small numbers of genotype 6 infected patients suggest that SOF-based regimens, including SOF + Ledipasvir (LDV) and SOF+ Ribavirin (RBV), are likely to be effective for most cases \[[@pone.0233446.ref013], [@pone.0233446.ref014]\], few data exist regarding the efficacy of treatment in resource poor settings.

The 'real world' effectiveness of medical treatments do not necessarily reflect their efficacy rates seen in clinical trials, and HCV infection is no exception \[[@pone.0233446.ref015], [@pone.0233446.ref016]\]. These differences likely reflect heterogeneities in patient characteristics, clinical practice, resources, care coordination, treatment drug combinations, and treatment adherence and duration, and become apparent only when a drug is prescribed to a wider population \[[@pone.0233446.ref005]\]. Real-world data on the effectiveness of DAAs in HCV genotype 6 infections from the geographic locations where it is prevalent are particularly limited \[[@pone.0233446.ref017]\]. Understanding the effectiveness of DAAs in such settings and in normal practice is crucial to inform policymakers when designing HCV treatment programs.

Vietnam is among the top 20 countries with the highest HCV burdens, with a population seroprevalence of between 0.9% and 1.2% \[[@pone.0233446.ref018]\]. DAAs have been the recommended first line treatment for HCV infection in Vietnam since 2016 \[[@pone.0233446.ref019]\]. All provincial hospitals and selected referral HCV treatment centers, including the Hospital for Tropical Diseases (HTD), Ho Chi Minh City, have prescribed DAA treatment since then, although the cost of this has been met by patients \[[@pone.0233446.ref017]\]. We present here our experience of the use of two sofosbuvir-based DAA regimens (SOF/LDV ± RBV, and SOF/Daclatasvir (DCV) ± RBV) in treatment-naïve patients infected with HCV genotype 1 or 6.

Materials and methods {#sec006}
=====================

Study description and ethical approval {#sec007}
--------------------------------------

We performed a retrospective, intent-to-treat cohort analysis of all chronic HCV (genotype 1 and 6) infected patients attending our hospital who began treatment with DAA combination therapy between March 2016 and October 2017. We include only DAA-inexperienced patients in the study; however, we did include patients who had previously failed to respond to treatment with non-DAA treatment history (i.e. Pegylated interferon (PegINF) and RBV). All DAA treatment was prescribed through the hospital pharmacy. To be included patients had to be age ≥18 years, infected with HCV genotype 1 or 6, and have initiated treatment with either SOF/LDV ± RBV, or SOF/DCV ± RBV. We excluded patients where the baseline and/or SVR HCV viral load data were unavailable including patients with incomplete treatment. The study received ethical approval from the Ethics Review Committee of the Hospital for Tropical Diseases (approval no CS/ND/16/02 date 23/11/2017).

Setting, patients and data extraction {#sec008}
-------------------------------------

The Hospital for Tropical Diseases (HTD), Ho Chi Minh City, is a 650-bed infectious disease hospital, and a designated specialized care provider and referral centre for patients with infectious hepatitis from the centre and south of Vietnam \[[@pone.0233446.ref010]\]. In 2015 HTD introduced an electronic record keeping system for the outpatients departments. These records include sociodemographic, clinical, imaging, prescribing, diagnostic and treatment outcome data for each patient under a unique identification number (ID). The HTD clinical laboratory maintains a separate database of all laboratory investigations conducted on patient samples; laboratory data are stored using a separate laboratory number linked to the unique patient ID. For this study, the hospital database was screened for the diagnosis of chronic HCV infection and treatment with DAAs. The hospital records management team extracted sociodemographic, clinical, laboratory and drug prescription and treatment outcome data for all eligible patients from the database according to the study proforma. All patient data were anonymized by replacing the patient identifier (unique ID) with a unique study number before transfer to the study investigators.

Data variables {#sec009}
--------------

Baseline variables were defined as the most recently available data prior to the initiation of DAA treatment (IOT). These included age, sex, geolocation (to the district level), liver cirrhosis status, diabetes, HIV and HBV infection status, hemoglobin, white blood count (WBC), platelet count, bilirubin, albumin, gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alpha-fetoprotein (AFP), blood glucose, HCV viral load and genotype, and Fibroscan score. Blood counts and biochemical tests were ascertained using a Sysmex XN-100 analyzer (Sysmex USA) and a Cobas 6000 analyzer (Roche, Basel, Switzerland) in the HTD clinical laboratory (ISO 15189; 2012 certified). Liver fibrosis was estimated using an Abbott FibroScan VCTE, (Abbott, Chicago, IL, USA). HCV viral load was measured using a commercial real-time polymerase chain reaction assay (COBAS AmpliPrep COBAS Taqman HCV Test version 2.0; Roche Molecular Diagnostics, Pleasanton, CA, USA), which defines a HCV viral load ≤15 IU/mL as "undetectable". HCV genotype was determined by "Real-time HCV Genotype assay II" using an Abbott m2000sp/rt system (Abbott Molecular Inc, Chicago, IL, USA). The fibrosis 4 (FIB-4) values were calculated using the formula age (years) × AST \[U/l\]/(platelets \[10^9^/l\] × (ALT \[U/l\])^1/2^). The APRI values were calculated using the formula "AST/upper limit of normal\]/platelet count \[10^9^/L\]" × 100 (the upper limit of normal of AST in our hospital is 37 IU/L for women and 40 IU/L for men) \[[@pone.0233446.ref020]\]. A FIB-4 \<1.45 indicates absence of fibrosis and \>3.25 indicates cirrhosis; an APRI score \<0.5 indicates absence of fibrosis, \>1.5 indicates fibrosis and \>2.0 indicates cirrhosis \[[@pone.0233446.ref021]\].

Treatment {#sec010}
---------

Patients received treatment according to the Vietnamese national guidelines at the time, summarised in [S1 Table](#pone.0233446.s001){ref-type="supplementary-material"} \[[@pone.0233446.ref022]\]. In line with these guidelines, the treatment regimen was selected based upon the HCV genotype and the presence or absence of cirrhosis. For patients without cirrhosis, the guidelines recommended a treatment duration of 12 weeks. Patients with cirrhosis were treated with either SOF/LDV or SOF/DCV for 24 weeks, or either of these combinations together with RBV for 12 weeks. The choice regarding these latter regimens was made by the physician in discussion with the patient.

SOF/LDV was given daily as a single oral fixed dose combination tablet consisting of 400 mg SOF and 90 mg LVD (sourced from any of Mylan Laboratories, India, Hetero Laboratories, India and M/s Natco Pharma, India). SOF/DCV was given as 400mg SOF and 30mg DCV once daily (sourced from Mylan Laboratories, India, Hetero Laboratories, India and M/s Natco Pharma, India). The treatment duration received by each patient was confirmed by review of prescriptions and the number of cumulative days' supply purchased by each patient, with purchase of medication for either 84 (12 weeks) or 168 days (24 weeks) from the hospital pharmacy being assumed to indicate the completion of 12 or 24 weeks of treatment respectively. We calculated the end of treatment (EOT) as the last day covered by the prescription related to the initial date of medication dispensing by the hospital pharmacy, cross-checked with the number of tablets bought. At HTD all patients receive advice on the importance of treatment adherence as per standard of care at each visit. Where doses are missed they are recommended to take the missed dose if within 16 hours of the due time. If more than 16 hours have elapsed, they are recommended to take the next dose at the due time.

Treatment outcome monitoring {#sec011}
----------------------------

HCV viral load was measured before IOT, at weeks 4, week 8 (if the HCV viral load was detectable at week 4), and either 12 or 24 weeks after the end of treatment (EOT, see [S2 Table](#pone.0233446.s002){ref-type="supplementary-material"}) \[[@pone.0233446.ref022]\]. Rapid virologic response (RVR) was defined as an HCV RNA \<15 IU/mL 4 weeks after IOT. Treatment success---sustained virological response (SVR) was defined as unquantifiable HCV RNA (LOD \<15 IU/mL) on all HCV RNA tests measured from 12 weeks or 24 weeks after the EOT or undetectable HCV RNA on last HCV RNA test 12 weeks or 24 weeks after EOT. Failure to achieve an SVR at 12 or 24 weeks after the EOT was defined as treatment failure. We defined breakthrough and relapse of infection as the achievement of an undetectable HCV RNA during treatment, followed by the detection of HCV RNA ≥15 IU/mL while on treatment (breakthrough), or after treatment completion (relapse).

Data analysis {#sec012}
-------------

Data analysis was performed using Statistical Package for Social Science (SPSS) software (IBM SPSS Statistics 23, NY USA). The main outcome of interest was the response to treatment. We analysed the success of the treatment on an intent to treat basis (n = 1758). Baseline descriptive statistics were summarized for the variables of interest. Comparisons between groups were performed using either the chi-squared or Fisher's exact tests for categorical variables; *t*-tests and the Mann-Whitney U-test were used for continuous variables. We used logistic regression to determine the baseline factors associated with SVR. A two-sided *P* value of ≤0.05 was considered statistically significant.

Results {#sec013}
=======

Enrollment {#sec014}
----------

From March 2016 to October 2017, 2817 patients infected with HCV attended the outpatient department at the HTD and initiated treatment with DAAs. Among these 369 patients had either genotype 2 or 3 infections and therefore were excluded from the analysis. Of the remaining 2448 patients, 684 were excluded because either baseline or SVR HCV viral load data were missing. Additionally, six patients treated with Elbasvir and Grazoprevir were excluded, resulting in 1758 patients available for analysis ([Fig 1](#pone.0233446.g001){ref-type="fig"}). Among the 1758 patients, 34.6% (610/1758) had genotype 1 infections and 65.4% (1148/1758) had genotype 6 infections. The 1758 patients had 4959 outpatient visits after IOT; 1401 patients (79.7%) had at least three more visits. HCV viral load at 4 weeks after IOT was available for 98.9% (1739/1758) of patients. Viral load at 12 week post-EOT only, both at 12 and 24 weeks post-EOT and at 24 weeks post-EOT only were available for 46.3% (814/1758), 44.8% (788/1753) and 8.9% (156/1758) patients respectively.

![Enrollment and analysis of patients.](pone.0233446.g001){#pone.0233446.g001}

Demographics {#sec015}
------------

[Table 1](#pone.0233446.t001){ref-type="table"} presents the baseline demographic and biochemical characteristics of the study population categorized by HCV genotype. The age of the patients (median; interquartile range (IQR)) was 57.0; 46--64 years. Patients with genotype 6 infections were slightly older than those with genotype 1 infections (mean age) 55.87 years versus 53.20 years; *p* = \<0.001, Mann Whitney U test). Overall there was a preponderance of female patients 56.9% (1001/1758). There was a preponderance of women amongst the genotype 6 infected cohort where they accounted for 59.8% of patients (95% confidence interval (CI) 57.0--62.6%; men 40.2%, 95%CI 37.4--43.0%, N = 1148). There was no difference in gender distribution amongst genotype 1 infections (women 51.5%, 95%CI 47.5--55.4%; men 48.5%, 95%CI 44.6--52.5%, N = 610). There was evidence of cirrhosis in 35.4% (622/1758) of patients and there was no difference in prevalence of liver cirrhosis between genotype 1 and 6 infected patients (*p* = .064, chi-squared test). There was a higher prevalence of HIV infection amongst patients with HCV genotype 1 infection than amongst patients with HCV genotype 6 infection (2.5% (15/610) versus 0.9% (10/1148) *p* = 0.008, chi-squared test) patients. There was no signification difference in HBV coinfection among genotype 1 and 6 patients (2.8%; (17/610) versus 2.7% (31/1148) *p* = 0.0531, chi-squared test). We found that markers of liver inflammation AST, ALT, AFP, GGT were statistically significantly higher in patients with genotype 1 infection, although the actual differences were small. In contrast, the HCV viral load was significantly higher in patients infected with genotype 6 virus compared with genotype 1 virus (6.6± 6.8 versus 6.3 ±6.5, *p* = \<0.001, Mann Whitney U test)). There was no significant difference in APRI and FIB-4 scores between patients infected with genotype 1 versus genotype 6. Patients infected with genotype 1 were more likely to have had a prior treatment failure episode with PegINF/RBV (7.0% (43/610) versus 4.7% (54/1148); *p* = 0.04, chi-squared test).

10.1371/journal.pone.0233446.t001

###### Baseline characteristics of all patients, and genotype 1 and 6 patients.

![](pone.0233446.t001){#pone.0233446.t001g}

                                                                                        All patient                   Genotype 1       Genotype 6       *P* value
  ------------------------------------------------------------------------------------- ----------------------------- ---------------- ---------------- ---------------------------------------------------------------------------------------------
  Age (years) [^β^](#t001fn002){ref-type="table-fn"}                                    57; 46--64                    55; 43--62       57; 48--65       \< .001[^\$^](#t001fn005){ref-type="table-fn"}^,^ [\*\*\*](#t001fn008){ref-type="table-fn"}
   \<40 [^δ^](#t001fn003){ref-type="table-fn"}                                          15.6 (274)                    20.5 (125)       13.0 (149)       
   41--55 [^δ^](#t001fn003){ref-type="table-fn"}                                        30.9 (544)                    30.5 (186)       31.2 (358)       
   \>55 [^δ^](#t001fn003){ref-type="table-fn"}                                          53.5 (940)                    49.0 (299)       55.8 (641)       
  Gender [^δ^](#t001fn003){ref-type="table-fn"}                                                                                                         \< .001 [^Ω^](#t001fn004){ref-type="table-fn"}^,^ [\*\*\*](#t001fn008){ref-type="table-fn"}
   Female                                                                               56.9 (1001)                   51.5 (314)       59.8 (687)       
   Male                                                                                 43.1 (757)                    48.5 (296)       40.2 (461)       
  Liver [^δ^](#t001fn003){ref-type="table-fn"}                                                                                                          0.064 [^Ω^](#t001fn004){ref-type="table-fn"}
   Non-cirrhosis                                                                        64.6 (1136)                   62.5 (381)       65.8 (755)       
   Compensated Cirrhosis                                                                34.9 (613)                    36.6 (223)       34.0 (390)       
   Decompensated Cirrhosis                                                              0.5 (9)                       1.0 (6)          0.3 (3)          
  Diabetes [^δ^](#t001fn003){ref-type="table-fn"}                                       3.1 (55)                      4.1 (25)         2.6 (30)         0.610 [^Ω^](#t001fn004){ref-type="table-fn"}
  HBV coinfection [^δ^](#t001fn003){ref-type="table-fn"}                                2.7 (48)                      2.8 (17)         2.7 (31)         0.531 [^Ω^](#t001fn004){ref-type="table-fn"}
  HIV coinfection [^δ^](#t001fn003){ref-type="table-fn"}                                1.4 (25)                      2.5 (15)         0.9 (10)         0.008 [^Ω^](#t001fn004){ref-type="table-fn"}^,^ [\*\*](#t001fn007){ref-type="table-fn"}
  BMI (kg/m2) [^α^](#t001fn001){ref-type="table-fn"}                                    22.73 ± 3.27 (13.42--38.89)   22.79 ±3.25      22.64 ±3.28      0.454[^\$^](#t001fn005){ref-type="table-fn"}
   \<18 [^δ^](#t001fn003){ref-type="table-fn"}                                          5.0 (70)                      4.3 (21)         5.3 (49)         
   18--25 [^δ^](#t001fn003){ref-type="table-fn"}                                        73.7 (1033)                   73.3 (355)       73.9 (678)       
   \>25 [^δ^](#t001fn003){ref-type="table-fn"}                                          21.3 (299)                    22.3 (108)       20.8 (191)       
  Fibroscan (Kpa) [^α^](#t001fn001){ref-type="table-fn"}                                12.77 ± 11.06                 13.22±11.99      12.52±10.53      0.732[^\$^](#t001fn005){ref-type="table-fn"}
  ALT (U/L) [^α^](#t001fn001){ref-type="table-fn"}                                      71.38 ± 58.52                 75.8 ± 59.8      69.0 ± 57.7      0.003[^\$^](#t001fn005){ref-type="table-fn"}^,^ [\*\*](#t001fn007){ref-type="table-fn"}
  AST (U/L) [^α^](#t001fn001){ref-type="table-fn"}                                      62.76 ± 43.74                 64.9 ± 41.3      61.5 ± 44.9      0.015[^\$^](#t001fn005){ref-type="table-fn"}
  Bilirubin (μmol/L) [^α^](#t001fn001){ref-type="table-fn"}                             7.70 ± 17.84                  10.1 ± 27.0      6.3 ± 9.1        0.739[^\$^](#t001fn005){ref-type="table-fn"}
  Creatinine (μmol/L) [^α^](#t001fn001){ref-type="table-fn"}                            72.74 ± 15.45                 73.9 ± 15.4      72.0 ± 15.4      0.030[^\$^](#t001fn005){ref-type="table-fn"}^,^ [\*](#t001fn006){ref-type="table-fn"}
  Albumin (g/L) [^α^](#t001fn001){ref-type="table-fn"}                                  40.63 ± 4.15                  40.5 ± 4.2       40.6 ± 4.0       0.863[^\$^](#t001fn005){ref-type="table-fn"}
  AFP (ng/ml) [^α^](#t001fn001){ref-type="table-fn"}                                    14.90 ± 42.76                 23.1 ± 64.9      10.7 ± 23.9      0.001[^\$^](#t001fn005){ref-type="table-fn"}^,^ [\*\*](#t001fn007){ref-type="table-fn"}
  GGT (U/L) [^α^](#t001fn001){ref-type="table-fn"}                                      71.41 ± 80.94                 82.8 ± 98.3      65.3 ± 69.2      0.001[^\$^](#t001fn005){ref-type="table-fn"}^,^ [\*\*](#t001fn007){ref-type="table-fn"}
  Glucose (mmol/L) [^α^](#t001fn001){ref-type="table-fn"}                               5.88 ± 1.74                   5.9 ± 2.0        5.8 ± 1.5        0.232[^\$^](#t001fn005){ref-type="table-fn"}
  HCV RNA [^δ^](#t001fn003){ref-type="table-fn"} (log IU/ml)                            6.5; 5.3--6.5                 6.3, 5.3--6.5    6.8, 5.3--6.6    0.001[^\$^](#t001fn005){ref-type="table-fn"}^,^ [\*\*](#t001fn007){ref-type="table-fn"}
   ≤6X10^6^ IU/mL [^δ^](#t001fn003){ref-type="table-fn"}                                45.5 (800)                    48.9 (298)       43.7 (502)       
   \>6X10^6^ IU/mL [^δ^](#t001fn003){ref-type="table-fn"}                               54.5 (958)                    51.1 (312)       56.3 (646)       
  APRI score [^α^](#t001fn001){ref-type="table-fn"}                                     6.8 ± 23.8                    6.48 ± 23.1      7.05 ± 24.0      0.319[^\$^](#t001fn005){ref-type="table-fn"}
   \<2 [^δ^](#t001fn003){ref-type="table-fn"}                                           5.0 (83)                      5.4 (31)         4.8 (52)         
   \>2 [^δ^](#t001fn003){ref-type="table-fn"}                                           95.0 (1565)                   94.6 (543)       95.2 (1022)      
  FIB-4 score [^α^](#t001fn001){ref-type="table-fn"}                                    8.9 ± 23.4                    8.54 ± 22.8      9.21 ± 23.8      0.350[^\$^](#t001fn005){ref-type="table-fn"}
   \<3.5 [^δ^](#t001fn003){ref-type="table-fn"}                                         25.1 (427)                    24.4 (146)       26.2 (281)       
   \>3.5 [^δ^](#t001fn003){ref-type="table-fn"}                                         74.1 (1221)                   70.2 (428)       73.8 (793)       
  Prior Therapy failure [^δ^](#t001fn003){ref-type="table-fn"}                          5.5 (97)                      7.0 (43)         4.7 (54)         0.040 [^Ω^](#t001fn004){ref-type="table-fn"}^,^ [\*](#t001fn006){ref-type="table-fn"}
  Treatment regimen [^δ^](#t001fn003){ref-type="table-fn"}                                                                                              
   SOF/LDV ± RBV                                                                        84.2 (1480)                   79.2 (483)       86.8 (997)       \<0.001 [^Ω^](#t001fn004){ref-type="table-fn"}^,^ [\*\*\*](#t001fn008){ref-type="table-fn"}
   SOF/DAC ± RBV                                                                        15.8 (278)                    20.8 (127)       13.2 (151)       
  Treatment duration (all patient) [^δ^](#t001fn003){ref-type="table-fn"}                                                                               
   12 week                                                                              94.6 (1694)                   95.2 (581)       97.0 (1113)      0.069 [^Ω^](#t001fn004){ref-type="table-fn"}
   24 week                                                                              3.6 (64)                      4.8 (29)         3.0 (35)         
  Treatment duration (compensated cirrhosis) [^δ^](#t001fn003){ref-type="table-fn"}                                                                     
   12 week                                                                              90 (552/613)                  88.3 (197/223)   91.0 (355/390)   0.326 [^Ω^](#t001fn004){ref-type="table-fn"}
   24 week                                                                              10 (61/613)                   11.7 (26/223)    9.0 (35/390)     
  Treatment duration (decompensated cirrhosis) [^δ^](#t001fn003){ref-type="table-fn"}                                                                   
   12 week                                                                              66.6 (6/9)                    50 (3/6)         100 (3/3)        0.464 [^Ω^](#t001fn004){ref-type="table-fn"}
   24 week                                                                              33.3 (3/9)                    50 (3/6)         0.0 (0/3)        
  Received Ribavirin [^δ^](#t001fn003){ref-type="table-fn"}                                                                                             
   Yes                                                                                  34.6 (608)                    35.4 (216)       34.1 (392)       0.596 [^Ω^](#t001fn004){ref-type="table-fn"}
   No                                                                                   65.4 (1150)                   64.6 (394)       65.9 (756)       
  Rapid Virological Response achieved [^δ^](#t001fn003){ref-type="table-fn"}                                                                            0.728 [^Ω^](#t001fn004){ref-type="table-fn"}
   Yes                                                                                  88.2 (1533)                   87.4 (528)       88.5 (1005)      
   No                                                                                   11.8 (206)                    12.6 (76)        11.5 (130)       

^α^: mean ±SD;

^β^: median; interquartile range;

^δ^: %(n)

^Ω^: Chi---square test;

^\$^: Mann Whitney U test;

\*: *p* = 0.01--0.05;

\*\*: *p*≤0.001--0.05;

\*\*\*: *p*\<0.001.

Treatment {#sec016}
---------

Details of the treatment prescribed are shown in [Table 1](#pone.0233446.t001){ref-type="table"}. Most patients (84.2%, 1480/1758) were treated with SOF/LDV± RBV; 15.8% (278/1758) were treated with SOF/DCV ± RBV. Patients with genotype 1 infections were more frequently treated with SOF/DAC±RBV than patients with genotype 6 infections (20.8% (127/610) versus 13.2% (151/1148); *p* = \<0.001, chi-squared test). The majority of patients with cirrhosis received treatment with ribavirin and DAAs for 12 weeks (compensated cirrhosis: 90.0% (522/613); decompensated cirrhosis 66.6% (6/9)). There was no difference in the use of the ribavirin-sparing 24 week treatment regimen between genotypes 1 and 6 patients (genotype 1: 4.8% (29/610) versus genotype 6: 3.0% (35/1148)). Patients who received 24 week treatment were significantly older (median; ±IQR) (60; 55--65 years versus 56; 46--64 years, *p* = 0.003, Mann Whitney U test), had higher liver stiffness (Kpa 30.9 ± 17.5 versus 12.2 ±10.3; *p* = \<0.001, Mann Whitney U test), higher APRI score (6.8 ± 23.9 versus 6.2 ± 20.8; *p* = \<0.001, Mann Whitney U test), and higher FIB4 score (11.7 ± 20.9 versus 8.8 ± 23.5; *p* = \<0.001, Mann Whitney U test) compared to patients who received 12 week treatment.

Effectiveness {#sec017}
-------------

Overall, 88.2% (1533/1739) of patients had RVR, (undetectable HCV viral loads \<15 IU/ml) by 4 weeks after IOT (Genotype 1: 87.4%, 528/604; genotype 6: 88.5%, 1005/1135, *p* = 0.54 chi-squared test, [Table 1](#pone.0233446.t001){ref-type="table"}). There was no significant difference in RVR rates between patients treated with SOF/LDV ± RBV versus SOF/DCV ± RBV (88.4%, 1293/1463 versus 87.0% 240/276, *p* = 0.280 chi-squared test). A RVR was significantly more likely to be seen in patients with baseline HCV viral loads \<6, 000,000 IU/ml than in those with viral loads ≥ 6, 000, 000 IU/mL (95.2%; 752/790 versus 82.3%; 781/949, *p* = \< 0.001 chi-squared test).

Final treatment outcomes are shown in [Table 2](#pone.0233446.t002){ref-type="table"}. SVR was achieved in 97.3% patients (1711/1758). Treatment failure was observed in 2.7% (47/1758) patients overall, and may have been slightly more common in patients with genotype 6 infections (3.2%; 37/1148 in genotype 6 infections versus 1.6%; 10/610 in genotype 1, *p* = 0.050 chi-squared test) [Table 2](#pone.0233446.t002){ref-type="table"}. We could not detect any influence of age, gender, cirrhosis, diabetes, HBV or HIV coinfection, BMI, APRI or FIB-4 index on the likelihood of achieving SVR. Patients who experienced treatment failure tended to have higher baseline viral loads than patients who experienced treatment success (6.7 ± 7.0 versus 6.4 ± 6.7 log IU/ml) although this is not statistically significant (*p* = 0.055, Mann Whitney U test). 3.3% (32/958) of patients with baseline viral load \>6,000,000 IU/ml had eventual treatment failure compared to 1.9% (15/800) with \<6,000,000 IU/ml (*p* = 0.058, chi-squared test). Attainment of a RVR did not predict an increased likelihood of eventual treatment success (SVR achieved in 97.4% (1493/1533) of patients who had RVR versus in 97.6%; (201/206) of patients who did not, *p* = 0.877, chi-squared test ([Table 2](#pone.0233446.t002){ref-type="table"}).

10.1371/journal.pone.0233446.t002

###### Comparison of baseline characteristics in patients according to eventual treatment outcome (sustained virological response, SVR for 1758 patients receiving SOF/LED ± RBV or SOF/DAC ± RBV.

![](pone.0233446.t002){#pone.0233446.t002g}

  Variable                                                              SVR achieved       SVR failure     P value
  --------------------------------------------------------------------- ------------------ --------------- ----------------------------------------------
  Genotype [^δ^](#t002fn003){ref-type="table-fn"}                                                          **0.050**
   Genotype 1                                                           98.4 (600/610)     1.6 (10/610)    
   Genotype 6                                                           96.8 (1111/1148)   3.2 (37/1148)   
  Age (years) [^β^](#t002fn002){ref-type="table-fn"}                    57, 57--64         58, 58--63      0.729[^\$^](#t002fn005){ref-type="table-fn"}
   \<40 [^δ^](#t002fn003){ref-type="table-fn"}                          97.4 (267/274)     2.6 (7/274)     0.967
   41--55 [^δ^](#t002fn003){ref-type="table-fn"}                        97.4 (530/544)     2.6 (14/544)    
   \>55 [^δ^](#t002fn003){ref-type="table-fn"}                          97.2 (914/940)     2.8 (26/940)    
  Gender [^δ^](#t002fn003){ref-type="table-fn"}                                                            0.261
   Female                                                               97.7 (978/1001)    2.3 (23/1001)   
   Male                                                                 96.8 (733/757)     3.2 (24/575)    
  Liver cirrhosis [^δ^](#t002fn003){ref-type="table-fn"}                                                   0.874
   Non cirrhosis                                                        97.3 (1105/1136)   2.7 (31/1136)   
   Compensated                                                          97.4 (597/613)     2.6 (16/613)    
   Decompensated                                                        100 (9/9)                          
  Diabetes [^δ^](#t002fn003){ref-type="table-fn"}                                                          0.653
   No                                                                   97.4 (1658/1703)   2.6 (45/1703)   
   Yes                                                                  96.4 (53/55)       3.6 (2/55)      
  HBV coinfection [^δ^](#t002fn003){ref-type="table-fn"}                                                   0.797
   No                                                                   97.3 (1664/1710)   2.7 (46/1710)   
   Yes                                                                  97.9 (47/48)       21\. (1/48)     
  HIV coinfection                                                                                          0.679
   No [^δ^](#t002fn003){ref-type="table-fn"}                            97.3 (1687/1733)   2.7 (46/47)     
   Yes [^δ^](#t002fn003){ref-type="table-fn"}                           96.0 (24/25)       4.0 (1/25)      
  BMI (kg/m2) [^α^](#t002fn001){ref-type="table-fn"}                    22.7 ±3.28         22.5 ± 2.86     0.752[^\$^](#t002fn005){ref-type="table-fn"}
   \<18 [^δ^](#t002fn003){ref-type="table-fn"}                          100 (70/70)        0 (0/0)         0.276
   18--25 [^δ^](#t002fn003){ref-type="table-fn"}                        96.7 (999/1033)    3.3 (34/1033)   
   \>25 [^δ^](#t002fn003){ref-type="table-fn"}                          97.3 (291/299)     2.7 (8/299)     
  APRI [^α^](#t002fn001){ref-type="table-fn"}                           6.8 ± 23.8         6.9 ± 24.3      0.999[^\$^](#t002fn005){ref-type="table-fn"}
   ≥ 2 [^δ^](#t002fn003){ref-type="table-fn"}                           96.4 (80/83)       3.6 (3/83)      0.584
   \< 2 [^δ^](#t002fn003){ref-type="table-fn"}                          97.4 (1524/1565)   2.6 (41/1565)   
  FIB-4 [^α^](#t002fn001){ref-type="table-fn"}                          8.9 ± 23.4         9.08 ± 23.9     0.704[^\$^](#t002fn005){ref-type="table-fn"}
   ≥ 3.5 [^δ^](#t002fn003){ref-type="table-fn"}                         97.7 (417/427)     2.3 (10/427)    0.625
   \< 3.5 [^δ^](#t002fn003){ref-type="table-fn"}                        97.2 (1187/1221)   2.8 (34/1221)   
  Baseline HCV RNA (log IU/mL) [^β^](#t002fn002){ref-type="table-fn"}   6.0, 6.0--6.6      6.3, 6.3--6.8   0.055[^\$^](#t002fn005){ref-type="table-fn"}
   ≤6000000 IU/mL [^δ^](#t002fn003){ref-type="table-fn"}                98.1 (785/800)     1.9 (15/800)    0.058
   \>6000000 IU/mL [^δ^](#t002fn003){ref-type="table-fn"}               96.7 (926/958)     3.3 (32/958)    
  RVR achieved [^δ^](#t002fn003){ref-type="table-fn"}                                                      0.877
   Yes                                                                  97.4 (1493/1533)   2.6 (40/1533)   
   No (≥15 IU/ml)                                                       97.6 (201/206)     2.4 (5/206)     
  Regimen [^δ^](#t002fn003){ref-type="table-fn"}                                                           0.164
   SOF/LDV± RBV                                                         97.1 (1437/1480)   2.9 (43/1480)   
   SOF/DAC± RBV                                                         98.6 (274/278)     1.4 (4/278)     
  Ribavirin [^δ^](#t002fn003){ref-type="table-fn"}                                                         0.312
   No                                                                   97.0 (1116/1150)   3.0 (34/1150)   
   Yes                                                                  97.9 (595/608)     2.1 (13/608)    
  Treatment time [^δ^](#t002fn003){ref-type="table-fn"}                                                    0.071
   12 weeks                                                             97.5 (1651/1694)   2.5 (43/1694)   
   24 weeks                                                             93.8 (60/64)       6.3 (4/64)      
  Prior treatment failure [^δ^](#t002fn003){ref-type="table-fn"}                                           0.302
   No                                                                   97.2 (1615/1661)   2.8 (46/1661)   
   Yes                                                                  99.0 (96/97)       1.0 (1/97)      

^α^: mean ±SD;

^β^: median; interquartile range;

^δ^: %(n)

^Ω^: Chi---square test;

^\$^: Mann Whitney U test.

There was no significant difference in treatment failure rates between patients treated with SOF/LED ± RBV versus SOF/DAC± RBV (2.9%; 43/1480 versus 1.4%; 4/278 *p* = 0.164 chi-squared test), or treated with or without RBV (n = 608) (2.1% (13/608) versus 3.0% (34/1150), *p* = 0.312, chi-squared test). Treatment failure was more frequent among patients treated with a 24 week regimen compared to a 12 weeks regimen (6.3%; 4/64 versus 2.5%; 43/1694), although this difference did not quite reach statistical significance (*p* = 0.071 chi-squared test). However, in patients infected with genotype 6, there appeared to be a marked increase in the rate of treatment failure in those receiving 24 weeks treatment rather than 12 (11.4% (4/35) versus 3.0% (33/1113); *p* = 0.005, chi-squared test).

We further examined the nature of treatment failure; whether it is a breakthrough or relapse. In 1739 patients, where RVR results were available 88.2% (1533/1739) achieved a RVR. All patients with RVR failure had undetectable HCV RNA when measured at 8 week after IOT. Those who achieved RVR (n = 1533), 2.6% (40/1533) had either viral breakthrough 4 weeks after IOT or viral relapse after EOT. The rate of breakthrough or relapse was significantly higher in genotype 6 patients compared to genotype 1 (3.3%; 33/1005 versus 1.3%; 7/528, *p* = 0.022 chi-squared test). Among 206 patients who failed to achieve a RVR, and subsequently had undetectable HCV RNA at 8 week IOT, only 2.4% (5/206) had treatment failure. The prevalence of treatment failure was not significantly different by virus genotype (1.3% genotype 1 (1 of 76) versus 3.1%; genotype 6 (4/130), *p* = 0.428 chi-squared test) in these patients. Among patients without RVR data (n = 19), 89.5% (17/19) achieved a SVR and 10.5% (2/19) had treatment failure.

In patients with treatment failure (n = 47), the mean baseline viral load was higher than those who achieved SVR (6.7 ± 7.0 versus 6.4 ± 6.4 log IU/ml; *p* = 0.055 Mann Whitney U Test). However, the majority of these patients attained RVR with viral relapse occurring 12 weeks after EOT.

A bivariate analysis was conducted to examine the effects of HCV genotype and baseline viral load on SVR or cure. Patients with genotype 1 had a higher probability of achieving cure (OR = 1.99; 95% CI: 0.98--4.04; *p* = 0.054). Similarly, patients with lower viral loads had a higher probability of achieving SVR (OR = 1.8, 95% CI = 0.97--3.36, *p* = 0.061) [Table 3](#pone.0233446.t003){ref-type="table"}.

10.1371/journal.pone.0233446.t003

###### Odds ratio for achieving SVR in 1758 HCV patients treated with SOF/LED ± RBV or SOF/DAC ± RBV.

![](pone.0233446.t003){#pone.0233446.t003g}

  Variable                   SVR rate           OR (95% CI)          P value
  -------------------------- ------------------ -------------------- ---------
  Age (years)                                                        0.967
   \<40                      97.4 (267/274)     1.08 (0.46--2.52)    0.850
   41--55                    97.4 (530/544)     1.07 (0.55--2.08)    0.825
   \>55                      97.2 (914/940)     1.00                 
  Gender                                                             
   Female                    97.7% (978/1001)   1.39 (0.78--2.48)    0.263
   Male                      96.8% (733/757)    1.00                 
  Liver cirrhosis                                                    
   Non cirrhosis             97.3 (1105/1136    1.00                 
   Compensated               97.4 (597/613)     1.04 (0.56--1.92)    0.884
   Decompensated             100 (9/9)          NA                   
  Diabetes                                                           
   No                        97.4 (1658/1703)   1.39 (0.32--5.88)    0.654
   Yes                       96.4 (53/55)       1.00                 
  HBV coinfection                                                    
   No                        97.3 (1664/1710)   1.00                 
   Yes                       97.9 (47/48)       1.29 (0.17--9.62)    0.798
  HIV coinfection                                                    
   No                        97.3 (1687/1733)   1.52 (0.20--11.53)   0.681
   Yes                       96.0 (24/25)       1.00                 
  BMI (kg/m2)                                                        
   \<18                      100 (70/70)        NA                   
   18--25                    96.7 (999/1033)    0.80 (0.37--1.76)    0.592
   \>25                      97.3 (291/299)     1.00                 
  APRI                       6.8 ± 23.8         1.00 (0.98--1.01)    0.978
   ≥ 2                       96.4 (80/83)       1.00                 
   \< 2                      97.4 (1524/1565)   1.39 (0.42--4.59)    0.586
  FIB-4                      8.9 ± 23.4         1.00 (0.98--1.01)    0.975
   ≥ 3.5                     97.7 (417/427)     1.19 (0.58--2.43)    0.626
   \< 3.5                    97.2 (1187/1221)   1.00                 
  Baseline HCV RNA (IU/mL)                                           
   ≤6000000 IU/mL            98.1 (785/800)     1.80 (0.97--3.36)    0.061
   \>6000000 IU/mL           96.7 (926/958)     1.00                 
  Genotype                                                           
   Genotype 1                98.4% (600/610)    1.99 (0.98--4.04)    0.054
   Genotype 6                96.8 (1111/1148)   1.00                 
  RVR achieved                                                       
   Yes                       97.4 (1493/1533)   1.00                 
   No (≥15 IU/ml)            97.6 (201/206)     1.07 (0.42--2.76)    0.877
  Regimen                                                            
   SOF/LDV± RBV              97.1 (1437/1480)   1.00                 
   SOF/DAC± RBV              98.6 (274/278)     2.05 (0.73--5.75)    0.173
  Ribavirin                                                          
   No                        97.0 (1116/1150)   1.00                 
   Yes                       97.9 (595/608)     1.39 (0.73--2.66)    0.314
  Treatment time                                                     
   12 weeks                  97.5 (1651/1694)   2.56 (0.86--7.36)    0.081
   24 weeks                  93.8 (60/64)       1.00                 
  Prior treatment failure                                            
   No                        97.2 (1615/1661)   1.00                 
   Yes                       99.0 (96/97)       2.73 (0.37--20.04)   0.322

Discussion {#sec018}
==========

We performed a retrospective review of HCV in our hospital in order to understand the response in patients infected with HCV genotype 6 to DAAs. Genotype 6 is the most frequent cause in our patients. There are a few data on the response of genotype 6 infections to DAAs, particularly in low-income settings. Our study addresses this knowledge gap and adds to the real-world data on the effectiveness of DAAs in genotype 6 in clinical practice \[[@pone.0233446.ref011], [@pone.0233446.ref012]\]. We compared treatment responses in patients infected with genotype 6 with those of patients infected with genotype 1 virus. We chose this comparison because i) current treatment guidelines recommend the same drug combinations can be used for each of these genotypes, and ii) the wealth of data from rich countries regarding the treatment response of genotype 1 infections allows us to set our experience in context. Our data add to the limited number of reports on treatment response that have emerged from Asian countries, including Vietnam \[[@pone.0233446.ref017], [@pone.0233446.ref023]\].

Similar to earlier studies, we documented a high prevalence (54.7% of cases) of HCV genotype 6 among patients attending our hospital \[[@pone.0233446.ref024]\]. This might be due to lower rate of spontaneous clearance of HCV genotype 6 than other genotypes or genotype 6 infections respond poorly to historical (non-DAA) anti-HCV therapy (e.g. PegINF±RBV) \[[@pone.0233446.ref018]\]. HCV genotype 6 is unique in many respects including i) localized geographic epidemiology (Laos, Cambodia, Vietnam, Myanmar, and Southern China), ii) high genetic diversity \[[@pone.0233446.ref009]\], iii) high number of preexisting drug resistance mutations \[[@pone.0233446.ref025]\], and iv) variable in-vitro susceptibility to DAAs (e.g. LDV) \[[@pone.0233446.ref025]\]. Compared with genotype 1 infections, we observed a higher prevalence of genotype 6 infection in women compared with men. The reasons for this is unclear, but it may represent inequalities in health care access between men and women in Vietnam. Historically treatment for HCV has been expensive and funded by the patient; fewer women may have had access to funds for treatment. The median age of patients in our study was 57 years. We found that patients with genotype 1 infections were younger then genotype 6 infected patients, and had higher rates of HBV and HIV coinfection. This points to some separation in the epidemics of genotype 6 and 1 infections in Vietnam. However, this being a retrospective study, we were unable to interrogate this further. It is feasible that the differences in genotype epidemics are associated with different risk behaviors (e.g. injectable drug use, man sex with man and sexual risk behavior) in the Vietnamese population at specific times. We found that patients with genotype 6 infections tended to have higher baseline viral loads than patients with genotype 1 infections. The consistency of this finding with previous studies suggests that genotype 6 virus may have a higher replication rate than genotype 1 virus \[[@pone.0233446.ref024]\].

Vietnamese guidelines at the time of this study suggested patients should receive either 12 weeks of treatment with or without RBV or 24 weeks of treatment without RBV depending upon the degree of their underlying liver disease. The majority of patients in our study received a 12 week treatment course. This is probably because the 12 week treatment course is significantly cheaper than 24 weeks, although patient convenience and adherence may also have been part of clinical decision making \[[@pone.0233446.ref024]\]. The American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian-Pacific Association for the Study of the Liver (APASL) recommend daily fixed-dose combination of i) glecaprevir/pibrentasvir for 8 weeks, ii) sofosbuvir/velpatasvir for 12 weeks, iii) SOF/LDV for 12 weeks, or iv) SOF/DAC for 12 weeks for treatment naïve HCV genotype 6 patients \[[@pone.0233446.ref026]--[@pone.0233446.ref028]\]. However, SOF/LDV is not currently recommended for treatment of subtype 6e infections\[[@pone.0233446.ref026]\]. There is a move towards recommending treatment durations for HCV infection (for example, as per AASLD guidelines); shorter durations of treatment can reduce costs and aid adherence. However, it is important that such recommendations for Asia are backed up by clinical trial evidence that includes patients with genotype 6 infections. Studies on treatment shortening are under evaluation in Vietnam.

We observed excellent cure rates (\>95%) in both patients with genotype 1 and genotype 6 HCV infections in our cohort, and cure rates were similar for both SOF/LDV and SOF/DAC combination therapy. We did not observed statistically significant difference in treatment outcomes between genotype 1 and 6 for these durations of treatment, although larger numbers of patients need to be evaluated to ensure this is true. We found cure rates of 96.8% (1111/1148) in genotype 6 infections versus 98.4% (600/610) in Genotype 1 (*p* = 0.05) infections. The slightly lower response we observed in genotype 6 infections could be explained by i) the higher baseline viral load in genotype 6 disease, ii) presence of pre-existing drug resistance mutations in genotype 6, and iii) the genetic diversity of genotype 6. A study from Myanmar found unexpectedly low SVR rates with sofosbuvir/ledipasvir combination treatment in genotype 6 infected patients \[[@pone.0233446.ref029]\]. In-vitro susceptibility studies have shown that there is variability amongst sub-lineages of genotype 6 virus to some DAAs. For example, *in vitro* resistance selection studies with LDV identified the single Y93H or Q30E resistance-associated variants (RAVs) in the NS5A gene in HCV genotype 6e. Similar RAVs were also observed in patients after a 3-day monotherapy treatment with LDV in genotype 1b \[[@pone.0233446.ref030]\]. Subtype 6e is also the predominant subtype in southern Vietnam. \[[@pone.0233446.ref018]\]. We do not have highly resolved genotype data for the infections in our study; however, the overall excellent response rates that we found suggest that either the treatment combinations used in our cohort are in fact highly effective across the genotype 6 subtypes, or subtype 6e is not frequent in our patients.

In our study, treatment failure was higher in patients treated with a 24-week regimen. This is possible because patients with cirrhosis (Child pugh B or C) are often treated with a 24-weeks regimen. These patients were older, had higher liver stiffness, high APRI and FIB-4 index and respond poorly to DAAs.

The vast majority of patients in our study had rapid virological responses, with undetectable viral loads by 4 weeks after treatment initiation. There was no difference in the rates of RVR by genotype. However, eventual cure rates were similar between patients who did and did not achieve RVRs, suggesting that viral load measured at this time point has little clinical utility where at least 12 weeks of treatment is prescribed and the patient is adherent. However, our experience contrasts with that of others where RVR has appeared to have a predictive value \[[@pone.0233446.ref031]\].

We could not determine whether the treatment failure was a result of relapse (SVR failure after EOT) or breakthrough (SVR failure during treatment) as viral load data at end of treatment was not available. However, based on the fact that 89.3% (42/47) treatment failure had RVR, one might speculate that most of the treatment failure were due to viral relapse after EOT or viral breakthrough 4 weeks after IOT. This suggests a possible adaptation/mutation in the viral genome or selection of resistant variants during the course of treatment. It has been reported that RVR and very rapid virologic response (vRVR; undetectable serum HCV RNA level at week 2) has a high positive but low negative predictive value of SVR with dual sofosbuvir/ribavirin therapy \[[@pone.0233446.ref032]\].

Our study is not without limitations. Our centre is a tertiary care centre and therefore the patients and outcomes may not be representative of the wider patient population in Vietnam. During the period of the study, HCV treatment was available only to self-funded patients. Given that DAA treatment was costing around \$2500/patient at the time, it is likely that most patients are wealthy and therefore patients from lower socioeconomic groups may not be represented. It was not possible to interrogate this with the available dataset. Our liver status data may be biased as we could only analyse the data from patients who could afford the test. Our study includes only patients who have completed the treatment as patients with incomplete treatment or discontinued treatment lacked SVR viral load data.

In conclusion, genotype 6 infection appears to be the predominant infecting HCV genotype in the south of Vietnam. Treatment outcomes in our tertiary referral centre were largely comparable to those in rich developed countries when treated for 12 weeks. It is possible that G6 outcomes are slightly worse than genotype 1, but any differences are small. However, there remains a need to generate evidence from randomized control trials on the best treatment combinations and options for patients in Asia infected with genotype 6.

Supporting information {#sec019}
======================

###### Treatment regimens and dose following Decision No. 5012/QĐ-BYT by MoH, Vietnam.

A; non cirrhotic chronic HCV, B; Chronic HCV with compensated cirrhosis (Child Pugh A), C: Chronic HCV decompensated cirrhosis (including moderate and severe liver failure, Child Pugh B or C), D: Doses of treatment.

(DOCX)
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Click here for additional data file.

###### Test recommendation before, during and after treatment of chronic HCV with DAA, DAA+RBV and PegINF+RBV+SOF (Issued together with Decision No. 5012/QĐ-BYT by MoH, Vietnam).

(DOCX)

###### 

Click here for additional data file.
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11\) Line 311: The parenthesis for "RVR" should be deleted from the text.

12\) Lines 313, 314, and 315: The numbers are incorrect?

13\) Line 401: The term is "difference", but not "different".

14\) Lines 407 to 409: All the patients with treatment failure were relapsers. None had viral breakthrough. The ETR rates should be clearly described!

15\) English language should be edited by a English-native speaker.
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to editors comments:

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

Response: No changes are made on financial disclosure.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.

Response to Reviewer's is uploaded.

• A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.

Revised Manuscript with Track change is uploaded

• An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

A file labeled Manuscript is uploaded.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: We have corrected the table and file name

2\. In your ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Response: The study received ethical approval from the Ethics Review Committee of the Hospital for Tropical Diseases (approval no CS/ND/16/02 date 23/11/2017). The ethics committee have waived the requirement for informed consent and as recommended by IRB, all data were fully anonymized by third party before handing over to the analysis team.

3\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Response: The data presented in the manuscript are extracted from the Hospital for Tropical Diseases, Ho Chi Minh City Vietnam and property of Hospital for Tropical Diseases, Ho Chi Minh City Vietnam. Institutional Review Board (IRB) of the Hospital for Tropical Diseases approved the access to fully anonymized dataset for analysis to the investigators and Oxford University Clinical research Unit (OUCRU). OUCRU has established a data sharing policy and the data can be accessed through the data sharing policy. All data presented in the manuscript can be accessed through "OUCRU data sharing policy" and request for access to data can be sent to <DAC@oucru.org>.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors conducted the real-world analysis aiming to evaluate the effectiveness of SOF based regimen in Vietnam. They demonstrated the overall SVR rates were 97.3% (1711/1758), and treatment failure ratios with different genotypes were: genotype 1, 1.7 % (10/610); genotype 6, 3.2% (37/1148). This study is well done and the manuscript is well written, but needs some modification for improvement.

1\. How come the results among those patients with active and HCC post curative therapies?

Do they exclude \"HCC\"?

Response: None of the patients included in the analysis had HCC

2\. Author should refer and compare APASL/AASLD/EASL guideline and the treatment for GT-6 patients including other regimens.

Response: We have included reference and APASL/AASLD/EASL guideline for treatment of HCV genotype 6. Please see Page 23 line 372 -- 378. We have also added necessary references (26-28).

3\. The difference of RAVs between G-6e and other G-6 could be discussed. Also, the treatment and retreatment regimens for the G-6e patients could be discussed.

Response: We thank the reviewer for their comments. We have added the following text: For example, in vitro resistance selection studies with LDV identified the single Y93H or Q30E resistance-associated variants (RAVs) in the NS5A gene in HCV genotype 6e. Similar RAVs were also observed in patients after a 3-day monotherapy treatment with LDV in genotype 1b please see page 24, line 395 -- 399.

Reviewer \#2: This original manuscript arouses interest for readers and provides an important clue to understand the epidemiology and properties of HCV genotype 6 and to treat patients with genotype 6 with DAAs. However, there are several issues that should be addressed or altered.

1\) Where were results of the end-of-treatment response (ETR) rates? Authors should specify the ETR rates. If the HCV RNA negativity was unknown at the completion or premature cessation of treatment, one could not identify the treatment outcomes, viral breakthrough or relapse.

Response: All patients are treated in accordance with the guidelines of the Vietnamese Ministry of Health for treatment of HCV infection. The guidelines mandate HCV viral load testing before initiation of treatment (IOT), at week 4 of treatment, again at week 8 if the patient had a detectable HCV viral load at week 4, and either 12 or 24 weeks after the end of treatment (EOT) (see S2 Table). The HCV viral load is not measured at the end of treatment and there therefore these data do not exist for any patient. Treatment cure is defined as an undetectable viral load measured between 12 and 24 weeks after completing treatment, and treatment failure as an HCV viral load ≥15 IU/ml 12 or more weeks after completing treatment).

We have revised the statement on viral breakthrough or relapse in the results and discussion section. Please see page 18-19, line 305-316 and page 25 line 418-422.

2\) Have all subjects completed the 12-week or 24-week treatment regimens? How many patients ceased treatment prematurely?

Response: All patients completed 12-week or 24-week treatment. Patients with prematurely ceased treatment lacks SVR viral load data and was excluded from analysis. Please see page 6, line 116-117 and page 26 line 433-435.

3\) Would you please inform us the patient and/or virological characteristics in more detail? Were there any differences in the characteristics between genotypes 1 and 6?

Response:

Tables 1 details differences between patients infected with HCV genotype 1 or 6. We found patients with genotype 6 infections were slightly older than those with genotype 1 infections (mean age) 55.87 years versus 53.20 years; p=\<0.001, Mann Whitney U test). Overall there was a preponderance of female patients 56.9% (1001/1758). There was a preponderance of women amongst the genotype 6 infected cohort where they accounted for 59.8% of patients (95% confidence interval (CI) 57.0 - 62.6%; men 40.2%, 95%CI 37.4 -- 43.0%, N = 1148). There was no difference in gender distribution amongst genotype 1 infections (women 51.5%, 95%CI 47.5 -- 55.4%; men 48.5%, 95%CI 44.6 -- 52.5%, N = 610). There was evidence of cirrhosis in 35.4% (622/1758) of patients and there was no difference in prevalence of liver cirrhosis between genotype 1 and 6 infected patients (p=.064, chi-squared test). There was a higher prevalence of HIV infection amongst patients with HCV genotype 1 infection than amongst patients with HCV genotype 6 infection (2.5% (15/610) versus 0.9% (10/1148) p=0.008, chi-squared test) patients. There was no signification difference in HBV coinfection among genotype 1 and 6 patients (2.8%; (17/610) versus 2.7% (31/1148) p=0.0531, chi-squared test). We found that markers of liver inflammation AST, ALT, AFP, GGT were statistically significantly higher in patients with genotype 1 infection, although the actual differences were small. In contrast, the HCV viral load was significantly higher in patients infected with genotype 6 virus compared with genotype 1 virus (6.6± 6.8 versus 6.3 ±6.5, p=\<0.001, Mann Whitney U test)). There was no significant difference in APRI and FIB-4 scores between patients infected with genotype 1 versus genotype 6. Patients infected with genotype 1 were more likely to have had a prior treatment failure episode with PegINF/RBV (7.0% (43/610) versus 4.7% (54/1148); p=0.04, chi-squared test).We addressed this in the results page 11, line 222-242.

4\) Line 153: the first "cirrhosis" is correct? Is the term "fibrosis"?

Response: We have changed the term "cirrhosis" to "fibrosis". Please see page 8 line 153.

5\) Lines 223 to 228: The descriptions in the text do not coincide with those in Table 1. Median or mean?

Response: The data presented in Table 1 is median and interquartile range. In line 223 we have compared mean age. We have corrected the text by including "mean age". Please see page 11, line 223.

6\) Lines 251 and 253: The descriptions do not coincide with those in Table 1.

Response: We have corrected the description. Please see page 14, line 251 and 253.

7\) Table 1: Which were two or three decimal places of decimals for p values? Table 1 should be more polished.

Response: we have presented all p values in three decimal. Please see table 1

8\) Line 264: "Rapid Virological Response" should be deleted from the text.

Response: We have made the change. Please see page 14, line 264

9\) Line 279 should be re-written.

Response: we have rephrased the sentence. Please see page 15, line 280

10\) Table 2: Look at the cell in Liver cirrhosis, Decompensated, SVR failure.

Response: we have made the correction, See Table 2

11\) Line 311: The parenthesis for "RVR" should be deleted from the text.

Response: We have made the change. Please see page 18, line 311-312

12\) Lines 313, 314, and 315: The numbers are incorrect?

Response: We have corrected the numbers. Please see page 18, line 313-315

13\) Line 401: The term is "difference", but not "different".

Response: We have made the change. Please see page 25, line 411

14\) Lines 407 to 409: All the patients with treatment failure were relapsers. None had viral breakthrough. The ETR rates should be clearly described!

Response: We thank the reviewer for their comments. We have added the following text: We could not determine whether the treatment failure was a result of relapse (SVR failure after EOT) or breakthrough (SVR failure during treatment) as viral load data at end of treatment was not available. However, based on the fact that 89.3% (42/47) treatment failure had RVR, one might speculate that most of the treatment failure were due to viral relapse after EOT or viral breakthrough 4 weeks after IOT. Please see page 25, line 417-421.

15\) English language should be edited by a English-native speaker.

Response: We have edited the English.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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